[/tdc_zone]
LATEST ARTICLES
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial...
LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...
Finding the silver lining: an update on the Roche GENERATION-HD1 trial...
The first round of findings from the halted tominersen huntingtin lowering trial, GENERATION-HD1, run by Roche were shared this week with the HD community....
Ionis’ partner to evaluate tominersen for Huntington’s disease in new Phase...
- Post-hoc analysis of GENERATION HD1 study data showed tominersen may have potential benefit in a subgroup of patients- Ionis' partner Roche is in...
UNIVERSITY
A NEW INTERNATIONAL CONSORTIUM TO PROMOTE STEM CELL-BASED THERAPY FOR HUNTINGTON’S...
The Stem Cells for Huntington’s Disease (SC4HD) is a new international consortium created to promote advanced therapy medicinal product (ATMP) through cell transplantation studies on...
New therapeutic target for Huntington’s treatment
Huntington’s disease is caused by a mutation in the Huntingtin gene (HTT), which appears in adults and features motor, cognitive and psychiatric alterations. The...
Optogenetic stimulation improves alterations in movement and behaviour of experimental models...
Huntington’s disease is an hereditary neurodegenerative disease featured by alterations in movement, cognitive deficiency and psychiatric disorders resulting from the degeneration of neurons in...
World first study reveals altered gut bacteria in Huntington’s Disease which...
The first clinical study of the gut microbiome in Huntington’s disease (HD) has found evidence of gut dysbiosis (altered bacteria in the gastrointestinal tract) in people...
HDBUZZ
Finding the silver lining: an update on the Roche GENERATION-HD1 trial...
The first round of findings from the halted tominersen huntingtin lowering trial, GENERATION-HD1, run by Roche were shared this week with the HD community....
Huntington’s disease therapeutics conference 2021 – Day 3
Catch up on all of the latest updates from day 3 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021
We are back for the...
ARTICLES
IONIS-HTTRx
